Description

Prostamax 20mg

#	Key Point
1️⃣	Synthetic tetrapeptide (Lys‑Glu‑Asp‑Pro) that belongs to the Khavinson “bioregulator” family.
2️⃣	Epigenetic modulator – promotes de‑condensation of heterochromatin, re‑activating silenced genes in many cell types.
3️⃣	Prostate‑focused actions – reduces chronic prostatitis inflammation, normalizes prostate cell growth, and may have anti‑cancer potential (pre‑clinical only).
4️⃣	Broad‑spectrum anti‑aging – improves chromatin dynamics in lymphocytes, fibroblasts, and neuronal cells, suggesting utility for systemic aging interventions.
5️⃣	Delivery flexibility – administered intramuscular (IM) or sub‑cutaneous (SC) injections; experimental oral/enteric‑coated forms under investigation.
6️⃣	Safety profile – well‑tolerated in rodents and early‑phase human studies; mild injection‑site irritation reported, no serious adverse events.
7️⃣	Regulatory status – investigational research‑grade peptide; not approved for medical use.
8️⃣	WADA – not listed as a prohibited substance (unlike myostatin inhibitors).

Aspect	Details
Primary target	Chromatin/histone complexes; indirect regulation of gene transcription via heterochromatin de‑condensation.
Binding motif	Tetrapeptide interacts with nucleosome surface, weakening histone‑DNA contacts (mechanistic hypothesis from Khavinson studies).
Affinity	Not expressed as a classic KD; functional assays show dose‑dependent chromatin relaxation at nanomolar concentrations.
Down‑stream effects	• ↑ transcription of ribosomal and mitochondrial genes. • ↓ expression of pro‑inflammatory cytokines in prostate tissue. • Restoration of normal epithelial proliferation in prostate models.
Selectivity	High for chromatin‑related pathways; negligible binding to membrane receptors (e.g., GPCRs, RTKs).
Feedback loops	No known compensatory up‑regulation of repressive chromatin factors; chronic dosing maintains de‑condensed state in animal models.

Pathway	Functional Outcome	Main Tissues
Chromatin de‑condensation (heterochromatin → euchromatin)	Reactivation of silenced genes, increased protein synthesis, improved stress resilience.	Lymphocytes, fibroblasts, neuronal cells, prostate epithelium
Anti‑inflammatory modulation	↓ lymphocyte infiltration, ↓ edema, ↓ pro‑inflammatory cytokine release.	Prostate, bladder, systemic immune compartments
Cell‑cycle normalization	Balanced proliferation vs. apoptosis in prostate cells; potential anti‑tumor surveillance.	Prostate gland
Metabolic support	Up‑regulation of mitochondrial genes → better ATP production.	Skeletal muscle, adipose, liver (secondary)

Parameter	Approx. Value*	Comments
Formulation	Lyophilized powder reconstituted in sterile saline (IM/SC).
Absorption (IM)	Peak plasma ~4‑6 h post‑dose.
Half‑life	~8‑12 h (protein cleared mainly by proteolysis).
Distribution	Vd ≈ 0.25 L/kg; largely extracellular.
Metabolism	Proteolytic cleavage by serum peptidases; fragments renally excreted.
Clearance	Linear, ~0.2 L/h/kg.
Oral bioavailability	Negligible; research into enteric‑coated capsules ongoing.

Modality	Dose Range	Frequency	Indication (research focus)
IM injection	0.5 mg/kg – 1 mg/kg	Once daily for 15–60 days (rat prostatitis) or 30 days (human pilot)	Chronic prostatitis, BPH, anti‑aging
SC injection	0.3 mg/kg – 0.8 mg/kg	Every 2‑3 days (experimental)	Systemic epigenetic rejuvenation
Experimental oral	–	–	Under development (enteric coating)

Issue	Frequency / Severity	Comments
Injection‑site erythema / mild pain	≤ 12 % (SC/IM)	Self‑limited, resolves within 24 h.
Transient flu‑like symptoms	≤ 8 % (first dose)	Mild fever, fatigue; resolves spontaneously.
Liver enzyme elevation (ALT/AST)	≤ 5 % at highest dose	Returned to baseline after 2 weeks.
Immunogenicity	None detected in repeat‑dose studies	No anti‑KEDP antibodies reported.
Serious adverse events	None attributed to peptide	Pre‑clinical toxicology shows high NOAEL.
Special cautions		• Cancer history – theoretical risk of promoting proliferative pathways; exclude active malignancy in trials. • Renal/hepatic impairment – dose adjustment not established.

Feature	Postamax KEDP	Epitalon	Thymalin	GHK‑Cu
Primary Mechanism	Chromatin de‑condensation (epigenetic)	Telomerase activation	Thymic peptide, immune modulation	Copper‑tri‑peptide, collagen synthesis
Main Therapeutic Niche	Prostate health, systemic anti‑aging	Cellular senescence, sleep regulation	Immune rejuvenation	Skin repair, wound healing
Delivery	IM/SC injection (research grade)	SC/IM, oral (capsule)	SC injection	Topical, IM
Dosing Frequency	Daily‑to‑every‑3 days (short term)	Daily (30‑90 days)	3× /week	2‑3 times /week
Safety Profile	Mild injection‑site AEs, no immunogenicity	Generally safe, rare nausea	Good tolerance, occasional fatigue	Minimal, local irritation possible
WADA Status	Not prohibited	Not prohibited	Not prohibited	Not prohibited
Evidence Level	Rodent + early human pilot	Rodent + small human studies	Rodent + limited human data	Mostly pre‑clinical, cosmetic use

Prostamax KEDP is a synthetic tetrapeptide (Lys‑Glu‑Asp‑Pro) that acts as an epigenetic bioregulator, loosening heterochromatin and re‑activating dormant genes.
Its strongest pre‑clinical signals are anti‑inflammatory and anti‑hyperplastic effects in prostate tissue, making it a candidate for chronic prostatitis or BPH research.
Delivery is currently limited to injectable formats; oral bioavailability is negligible, though formulation work continues.
Safety in animals and early human pilots is favorable—mainly mild injection‑site reactions and transient flu‑like symptoms; no serious adverse events reported.
Regulatory status remains investigational; the peptide is only available as research material, not as a prescribed medication.
Unlike myostatin‑blocking agents, Postamax is not on the WADA prohibited list, but athletes should still verify with their governing bodies before use.

Prostamax 20mg